After Columbia arrests, international college students fall silent
A river ‘died' overnight in Zambia after an acidic waste spill at a Chinese-owned mine
Driverless 'bus of the future' is tested in Barcelona
US designated South Korea a 'sensitive' country amid talk of nuclear weapons
Magnitude 5.5 earthquake hits southern Mexico, alarms sound in capital
Critics warn staff cuts at federal agencies overseeing US dams could put public safety at risk
Zuby Ejiofor much more than just most improved in record-setting performance for No. 6 St. John's
Withers' lane violation adds improbable twist to UNC's failed comeback against No. 1 Duke in ACCs
F1 hometown driver Piastri fastest in final practice ahead of Australian GP qualifying
By Michael Erman
(Reuters) - Merck & Co on Thursday reported better-than-expected fourth-quarter results on strong sales of its cancer immunotherapy Keytruda, now the world's biggest selling prescription medicine.
Merck reported adjusted earnings of 3 cents a share in the quarter, despite having to reduce its profit by $1.69 a share to account for a $5.5 billion payout to Japan's Daiichi Sankyo for the right to co-develop three cancer drugs. Analysts, on average, had expected the company to lose 11 cents a share, according to LSEG data.
Revenue for the quarter rose to $14.6 billion from $13.8 billion last year. Analysts, on average, had expected sales of $14.5 billion.
Sales of Keytruda rose 21% to $6.6 billion as the company was able to increase use of the drug in earlier stage cancers, topping analyst forecasts of $6.5 billion. For the full year, Keytruda racked up $25 billion in sales, surpassing sales of AbbVie's blockbuster arthritis drug Humira at its peak.
Merck forecast 2024 sales of between $62.7 and $64.2 billion, suggesting growth of as much as 6.8% year over year. Analysts, on average, are estimating 2024 sales of $63.5 billion.
The New Jersey-based drugmaker expects earnings of $8.44 to $8.59 per share, above analyst estimates of $8.42.
The company also said it is launching a restructuring program to optimize both its human health and animal health manufacturing operations.
It did not disclose any other details. Merck recorded a $190 million charge to its GAAP results in the quarter related to the restructuring.
Including costs from deals other than the Daiichi transaction and restructuring costs, the company reported a net loss of 48 cents per share for the quarter.
(Reporting by Michael Erman; Editing by Bill Berkrot)
